62
Participants
Start Date
December 31, 2007
Primary Completion Date
December 31, 2010
Study Completion Date
October 31, 2011
bevacizumab
10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
temozolomide
150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
Kantonsspital Graubuenden, Chur
Swiss Cancer Institute
OTHER